1. Administration, Food and Drug (2015) Biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009: guidance for industry. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf. Zugegriffen im 11.2019
2. Agency, European Medicines (2014) Rev1: guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. Zugegriffen im 11.2019
3. Alcorn J, McNamara PJ (2003) Pharmacokinetics in the newborn. Adv Drug Deliv Rev 55:667–686
4. van den Anker JN, Schwab M, Kearns GL (2011) Developmental pharmacokinetics. Handb Exp Pharmacol 205:51–75
5. Arthur S, Burgess A (2017) How to identify and manage ‚problem‘ excipients in medicines for children. Pharm J 299:42–45